Acepromazine (PromAce)

Acepromazine, commonly known by the brand name PromAce, is a phenothiazine tranquilizer that has been a mainstay in veterinary medicine for decades. In guinea pig medicine, acepromazine serves primarily as a pre-anesthetic agent to calm patients before procedures and as a chemical restraint option for diagnostic examinations or minor interventions. While newer sedation options have expanded the exotic veterinarian's toolkit, acepromazine remains a useful medication when its specific properties match the clinical situation, providing reliable sedation with a well-understood pharmacological profile.

The mechanism of action involves blocking dopamine receptors in the central nervous system, producing sedation, reduced anxiety, and muscle relaxation. Acepromazine also has antihistamine and anticholinergic properties that contribute to its clinical effects. The drug does not provide analgesia, meaning that while the guinea pig becomes calm and less reactive, pain sensation is not blocked. This characteristic is important when planning procedures, as additional pain management must be incorporated when painful stimuli are anticipated. The sedation produced is typically characterized by calmness and reduced responses to stimuli rather than true sleep.

Acepromazine is available in injectable formulation at concentrations of ten milligrams per milliliter, which is diluted for use in small patients like guinea pigs to allow accurate dosing. Tablets are also manufactured but are rarely used in guinea pig medicine due to dosing challenges and variable oral absorption in this species. The injectable form is administered either intramuscularly or subcutaneously, with onset of action typically occurring within fifteen to thirty minutes depending on the route. Duration of sedation varies but commonly lasts two to four hours, making appropriate timing of administration relative to planned procedures essential.

The safety profile of acepromazine in guinea pigs requires careful consideration of both the benefits and potential risks associated with its use. While the medication has a relatively wide safety margin compared to some other sedatives, guinea pigs are more sensitive to phenothiazines than some other species, necessitating conservative dosing. Significant hypotension can occur, making acepromazine less suitable for debilitated patients or those with cardiovascular concerns. The medication causes peripheral vasodilation, which can lead to hypothermia in small patients if environmental temperature is not carefully controlled. Veterinary supervision by an exotic animal specialist is essential for any acepromazine use in guinea pigs to ensure appropriate patient selection, dosing, and monitoring throughout the sedation period.

The primary indication for acepromazine in guinea pig medicine is pre-anesthetic sedation to prepare patients for procedures requiring general anesthesia. By calming the patient before anesthetic induction, acepromazine reduces the total amount of general anesthetic needed, smooths the induction process, and decreases the risk of complications associated with excited or struggling patients. Guinea pigs that are anxious or resistant during handling can be particularly challenging to anesthetize safely, and appropriate pre-medication addresses this concern. The sedation also reduces the stress response to handling and preparation, which has physiological benefits for the sensitive guinea pig patient.

Chemical restraint for diagnostic procedures represents another common application of acepromazine in guinea pig practice. Radiography, ultrasound examinations, and certain physical examination procedures may be difficult to perform adequately on alert, mobile guinea pigs. The sedation provided by acepromazine allows the veterinarian to position the patient appropriately and complete diagnostic imaging with reduced motion artifact and patient stress. For guinea pigs that cannot be adequately examined while awake due to resistance or anxiety, mild sedation facilitates thorough physical assessment including oral examination, abdominal palpation, and evaluation of hard-to-examine areas.

Minor procedures that do not require general anesthesia may be performed under acepromazine sedation combined with local anesthesia when appropriate. Wound cleaning and bandage changes, abscess drainage when combined with local anesthetic, and other brief interventions can sometimes be accomplished with acepromazine-induced sedation rather than full anesthesia. The decision to use this approach depends on the specific procedure, the patient's temperament and health status, and the veterinarian's assessment of whether adequate chemical restraint can be achieved without general anesthesia. Pain management must be addressed separately since acepromazine does not provide analgesia.

Transport stress reduction is an occasional indication for acepromazine use, though this application requires careful consideration of the risks and benefits. Long-distance transport to specialty facilities or situations where handling is unavoidable may be made safer for extremely anxious guinea pigs with appropriate sedation. However, the hypotensive and hypothermic effects of acepromazine can be problematic during transport when monitoring is limited, and many practitioners prefer other anxiolytic options for this purpose. When used for transport, careful instructions regarding temperature control and monitoring must be provided.

The selection of acepromazine over alternative sedation options depends on several factors specific to the patient and clinical situation. Acepromazine is often chosen when cost considerations are relevant, as it is relatively inexpensive compared to newer sedation protocols. It may be preferred when a longer duration of effect is desired without repeated dosing. The medication is not a controlled substance, simplifying storage and documentation requirements. For patients where alpha-2 agonists are contraindicated due to cardiovascular concerns, acepromazine may provide an alternative, though its own cardiovascular effects require consideration. The exotic veterinarian evaluates each situation individually to determine the most appropriate sedation approach.

The dosing protocol for acepromazine in guinea pigs requires precise calculation and dilution due to the small size of these patients and their sensitivity to phenothiazine effects. All dosing decisions and administration must be performed by or under the direct supervision of an exotic animal veterinarian experienced in guinea pig care. The typical dose range for guinea pigs is 0.5 to 1.0 milligrams per kilogram administered intramuscularly or subcutaneously, with many practitioners using doses at the lower end of this range due to guinea pig sensitivity. Body weight must be measured accurately using a gram scale immediately before dose calculation.

Stock acepromazine solution at ten milligrams per milliliter is far too concentrated for direct use in guinea pig patients, requiring dilution to allow accurate measurement of small doses. A common dilution protocol creates a one milligram per milliliter solution by adding 0.1 milliliters of stock acepromazine to 0.9 milliliters of sterile saline. This dilution allows accurate measurement of doses appropriate for guinea pig body weights using a one-milliliter tuberculin syringe. For a one-kilogram guinea pig receiving 0.5 milligrams per kilogram, the dose would be 0.5 milliliters of the diluted solution. Fresh dilutions should be prepared for each patient or series of patients on a given day, as diluted solutions do not have extended stability.

Onset of action following intramuscular injection typically occurs within ten to twenty minutes, with peak sedation reached at approximately thirty to forty-five minutes. Subcutaneous administration results in slower, more variable absorption with onset times of twenty to forty minutes being common. The intramuscular route is generally preferred when predictable timing is needed, while subcutaneous administration may be used when avoiding muscle injection is desirable. Regardless of route, adequate time must be allowed for the medication to take effect before proceeding with the planned procedure or anesthetic induction.

Duration of sedation from acepromazine typically ranges from two to four hours in guinea pigs, though individual variation is significant. Some patients may show effects for longer periods, particularly if higher doses were used or if metabolism is slowed by concurrent illness or liver compromise. Planning for adequate observation time during recovery is essential. The prolonged duration makes acepromazine less suitable for brief procedures where rapid recovery is desired, but advantageous when extended sedation facilitates longer procedures or multiple sequential interventions.

If sedation appears inadequate after appropriate waiting time, the situation requires careful assessment before any additional medication is administered. Supplemental acepromazine dosing is possible if the total dose remains within safe limits, but the slow onset means that additional doses given too soon can result in cumulative oversedation as all doses eventually take effect. Many practitioners prefer to supplement with different medication classes such as midazolam or opioids rather than redosing acepromazine, allowing for more predictable effects. The veterinarian makes this determination based on the specific situation and planned procedure requirements.

Recovery from acepromazine sedation requires continued monitoring in a warm, quiet environment. Guinea pigs should be placed in a secure cage with soft bedding, away from ledges or heights that could pose fall risks while coordination is impaired. Temperature support through supplemental heating ensures the vasodilated patient does not become hypothermic. Hay and water should be available for when the guinea pig is alert enough to eat, typically within one to two hours after procedures though full recovery may take longer. The patient should not be returned to multi-guinea pig housing until coordination and alertness have fully returned to prevent injury from cage mates.

Acepromazine is generally tolerated by guinea pigs when administered at appropriate doses by experienced practitioners, but its pharmacological effects predictably produce several side effects that must be anticipated and managed. Understanding these expected effects allows for appropriate preparation and monitoring, distinguishing normal medication responses from concerning adverse reactions.

The most consistently observed effect is hypotension, a direct consequence of acepromazine's alpha-adrenergic blocking activity causing peripheral vasodilation. In guinea pigs, this blood pressure decrease is generally well-tolerated in healthy patients but can become problematic in debilitated or dehydrated individuals. Visible manifestations may include pale mucous membranes, prolonged capillary refill time, and generalized weakness. Subcutaneous or intravenous fluid support may be indicated during procedures to maintain circulating volume and support blood pressure. Pre-existing cardiovascular compromise increases hypotension risk significantly.

Hypothermia commonly develops in guinea pigs sedated with acepromazine due to the combination of vasodilation increasing heat loss, reduced activity eliminating heat generation from movement, and impaired thermoregulation from central sedation. Guinea pigs are already vulnerable to temperature fluctuations due to their small body mass and high surface-area-to-volume ratio. Active warming measures including heated surfaces, warm water bottles appropriately wrapped to prevent burns, and maintaining elevated ambient temperature in the procedure and recovery areas are essential components of acepromazine sedation management.

Prolonged sedation beyond the expected timeframe occurs in some patients, particularly those with compromised liver function since acepromazine undergoes hepatic metabolism. Older guinea pigs may also experience extended duration of effect. While prolonged sedation itself is not necessarily harmful if the patient is otherwise stable, it can be concerning for owners and delays return to normal function. Extended sedation also means extended risk periods for hypothermia and pressure-related complications if positioning is not changed periodically.

Serious adverse effects requiring immediate intervention are uncommon with appropriate dosing but include severe hypotension manifesting as collapse or shock, seizures (more common in patients with pre-existing seizure disorders or those receiving other drugs that lower seizure threshold), and paradoxical excitation where instead of sedation, the patient becomes agitated and hyperactive. Severe allergic reactions are rare but possible with any medication. Any guinea pig showing signs of respiratory distress, severe weakness, seizure activity, or unexpected behavior changes following acepromazine administration requires immediate veterinary assessment and supportive care. Emergency interventions may include intravenous fluids, warming measures, oxygen supplementation, and in some cases, medication to counteract the sedation though complete pharmacological reversal is not available for phenothiazines as it is for some other sedative classes.

Acepromazine should not be administered to guinea pigs with known hypersensitivity to phenothiazine medications. While allergic reactions to acepromazine are uncommon, any guinea pig that has shown signs of adverse reaction to previous phenothiazine exposure should not receive this medication again. Reactions may include excessive swelling at injection sites, respiratory difficulty, or other signs of hypersensitivity. Alternative sedation protocols using different drug classes should be selected for these patients.

Cardiovascular disease represents a significant contraindication for acepromazine use due to its hypotensive effects and cardiac conduction effects. Guinea pigs with known heart murmurs, congestive heart failure, cardiomyopathy, or any form of cardiovascular compromise are at elevated risk for decompensation when vasodilation and blood pressure reduction occur. The combination of pre-existing cardiac limitations with acepromazine-induced cardiovascular changes can precipitate acute heart failure or collapse. For guinea pigs requiring sedation who have cardiovascular disease, alternative protocols with less cardiovascular impact should be selected in consultation with the veterinarian.

Hypovolemia, dehydration, or shock are absolute contraindications for acepromazine administration. Patients who are already volume-depleted cannot compensate for the additional vasodilation caused by acepromazine, and severe hypotension or cardiovascular collapse can result. Guinea pigs presenting for procedures while dehydrated must be rehydrated before sedation is considered, and those in shock require stabilization with fluid therapy and supportive care before any sedation or anesthesia. The clinical assessment of hydration status through skin turgor, mucous membrane moisture, and recent history of intake must be completed before acepromazine is given.

Certain other conditions and patient factors limit or preclude acepromazine use. Patients with seizure disorders may experience lowered seizure threshold from acepromazine, increasing the risk of seizure activity. Liver disease impairs acepromazine metabolism and can result in unpredictable duration and intensity of effects; significant hepatic compromise is a contraindication while mild disease requires dose reduction and enhanced monitoring. Guinea pigs with severe debilitation from any cause are poor candidates for acepromazine due to limited physiological reserve for compensating drug effects. Pregnant guinea pigs require careful consideration, as acepromazine crosses the placenta and could potentially affect fetal circulation, though the drug has been used when the benefits outweigh risks in specific clinical situations. Very young guinea pigs under two to three weeks of age have immature drug metabolism and should generally not receive acepromazine.

Complete disclosure of all medications, supplements, and recent treatments is essential before acepromazine administration to allow the veterinarian to identify potential interactions and adjust the sedation plan accordingly. Acepromazine has numerous potential interactions due to its multiple pharmacological effects on cardiovascular, neurological, and hepatic systems. Even medications that might seem unrelated to sedation can influence acepromazine's safety and efficacy.

The most significant interactions involve other drugs with cardiovascular or central nervous system depressant effects. Concurrent administration of other sedatives, tranquilizers, or anesthetics produces additive or synergistic depression, potentially resulting in oversedation, excessive cardiovascular depression, or respiratory compromise. While intentional combinations are commonly used in veterinary medicine to achieve balanced anesthesia, these require careful dose reduction of each component and experienced management. Opioid pain medications commonly combined with acepromazine for pre-anesthetic protocols potentiate both sedation and cardiovascular effects. Antihypertensive medications, though rarely used in guinea pigs, would have additive effects with acepromazine-induced hypotension.

Medications affecting hepatic metabolism can alter acepromazine's duration and intensity of effect. Cimetidine and certain other drugs that inhibit hepatic cytochrome P450 enzymes slow acepromazine metabolism, potentially prolonging and intensifying sedation. Conversely, drugs that induce hepatic enzymes might theoretically shorten duration, though this interaction is less commonly documented. Guinea pigs receiving any medications metabolized by the liver should have this information considered when planning acepromazine sedation.

Organophosphate compounds, which guinea pigs might encounter through certain antiparasitic treatments, can have dangerous interactions with acepromazine. While modern antiparasitic protocols typically avoid organophosphates in guinea pigs, any recent exposure should be disclosed. The interaction can potentiate toxicity of both compounds. Similarly, certain antibiotics that might lower seizure threshold could interact unfavorably with acepromazine's own seizure threshold-lowering potential. Vitamin C supplementation, essential for guinea pigs, does not interact directly with acepromazine but should be continued throughout any treatment period to support overall health. Maintaining normal hay and vegetable intake supports gut motility, which can be slowed during sedation, reducing the risk of gastrointestinal stasis. The veterinarian considers all these factors when developing the sedation protocol for each individual guinea pig patient.

Fundamental precautions for acepromazine use in guinea pigs begin with the requirement for veterinary supervision by practitioners experienced in exotic animal sedation. The drug's cardiovascular effects, temperature regulation impacts, and prolonged duration of action create risks that require professional monitoring and the ability to provide supportive intervention if complications arise. Acepromazine should only be administered in facilities equipped to monitor sedated patients, maintain body temperature, and provide emergency support if needed. Home administration by owners is never appropriate.

Specific breed considerations affect acepromazine use planning, though pharmacological differences between guinea pig breeds have not been documented. Hairless breeds including Skinny pigs are at increased risk of hypothermia due to lack of insulating fur, requiring more aggressive temperature support during and after acepromazine sedation. Long-haired breeds may obscure visual assessment of injection sites and monitoring of capillary refill at mucous membranes. Individual temperament varies between guinea pigs regardless of breed, and those who are particularly anxious may paradoxically require lower doses as stress may exacerbate acepromazine's cardiovascular effects, while extremely calm individuals may require doses at the higher end of the range for adequate effect.

Environmental management during acepromazine sedation is critical for patient safety. The procedure area should be maintained at elevated temperature, typically around 80-85°F (27-29°C), to minimize heat loss from the vasodilated patient. Draft-free conditions prevent convective heat loss. Active warming devices should be available and used throughout the sedation period. Lighting should be subdued to promote calm, and loud noises should be minimized. The recovery area should provide similar environmental control and be secure against falls or escape attempts by partially sedated patients.

Monitoring protocols during acepromazine sedation include regular assessment of respiratory rate and effort, heart rate when assessable, mucous membrane color and capillary refill time as indicators of cardiovascular status, body temperature, and depth of sedation. Baseline values should be documented before medication administration for comparison. Temperature should be measured at least every fifteen minutes during procedures and recovery, with warming measures adjusted as needed. Any deterioration in monitored parameters prompts reassessment and intervention.

Special populations require enhanced precautions or alternative sedation approaches. Senior guinea pigs over three years of age often have subclinical organ compromise that affects drug handling and compensation capacity; lower doses and extended monitoring are appropriate. Debilitated patients from any cause have limited physiological reserve and may decompensate with acepromazine's cardiovascular effects. Guinea pigs with respiratory disease may experience worsened respiratory function during sedation. Pregnant sows require consideration of fetal effects. Young guinea pigs under appropriate weaning age should generally not receive acepromazine. The veterinarian evaluates each patient individually to determine whether acepromazine is appropriate and what specific precautions are needed.

Acepromazine injectable solution should be stored at controlled room temperature between fifteen and thirty degrees Celsius (59-86°F), protected from light exposure which can cause degradation. The medication should be kept in its original amber or light-protective container, and if transferred to other containers for dilution, these should also provide light protection or the diluted solution should be used promptly. Freezing must be avoided as it can alter the solution's chemical properties. The storage location should be secure, away from guinea pig habitats, and inaccessible to children and unauthorized personnel.

Visual inspection before each use helps ensure medication integrity and patient safety. Acepromazine solution should be clear and colorless to very slightly yellow; any significant discoloration, cloudiness, or visible particulate matter indicates potential degradation or contamination and the vial should be discarded. Precipitate formation or crystals suggest chemical breakdown. Multi-dose vials should be examined for any contamination of the rubber stopper and dated when first opened. Opened multi-dose vials have limited stability and should be used within the timeframe specified by the manufacturer or facility protocols, typically not exceeding thirty days after opening. Expiration dates on all containers must be checked before use, and expired medications properly disposed of regardless of appearance.

Diluted acepromazine solutions for small patient dosing have limited stability and should ideally be prepared fresh for each patient or day of use. If diluted solutions must be stored briefly, they should be clearly labeled with contents, concentration, date, and time of preparation, and stored protected from light. Most practitioners discard diluted solutions at the end of each clinic day rather than attempting to store them. Using sterile saline or appropriate diluent from single-use containers for dilution helps prevent contamination.

Safe handling and disposal practices protect the environment and personnel. While acepromazine is not a controlled substance, appropriate handling precautions should still be observed. Accidental injection or significant skin exposure in humans can cause drowsiness and should prompt medical consultation. Sharps disposal protocols apply to all needles and syringes used. Pharmaceutical waste including unused medication and containers should be disposed of according to local regulations and facility policies. Drug take-back programs offer an environmentally responsible disposal option when available, keeping medications out of landfills and water supplies.

The majority of guinea pig breeds respond similarly to acepromazine from a pharmacological standpoint, with dosing determined primarily by body weight rather than breed-specific factors. However, certain breed characteristics create practical considerations that experienced exotic veterinarians incorporate into their sedation protocols. Awareness of these factors helps ensure optimal outcomes across the variety of guinea pig breeds encountered in practice.

Hairless guinea pig breeds require particular attention to thermoregulation during acepromazine sedation. Skinny pigs, which retain some hair on their faces and feet, and Baldwin guinea pigs, which are completely hairless, lack the insulating fur coat that helps other guinea pigs maintain body temperature. Combined with acepromazine-induced vasodilation, these breeds are at significantly elevated risk of hypothermia during sedation. More aggressive active warming measures are essential, including heated surfaces, warm water bottles appropriately wrapped, and elevated ambient temperature. Temperature monitoring should be more frequent in hairless breeds, and recovery in a warm environment is critical.

Long-haired breeds including Peruvians, Silkies, Coronets, and Texels present practical rather than pharmacological considerations. The dense, lengthy coat may make physical examination of sedated patients more challenging and can obscure injection site assessment for swelling or complications. Mucous membrane color assessment for monitoring cardiovascular status requires parting facial hair in heavily coated individuals. These breeds may actually have some advantage regarding thermoregulation compared to hairless guinea pigs due to their insulating coat, but temperature monitoring remains important. Grooming of long coats is not possible during sedation, and the coat may become soiled if the guinea pig is positioned on its side; consideration of coat care during recovery may be relevant for show animals.

Size variation within the guinea pig population affects acepromazine dosing precision. Adult guinea pigs typically range from seven hundred to twelve hundred grams, with considerable individual variation. Smaller guinea pigs require proportionally precise dose calculation and accurate dilution of the medication to allow measurement of small volumes. Large guinea pigs have slightly more margin for minor measurement variations. Age-related considerations include potentially decreased hepatic function in senior guinea pigs over three years of age, which may prolong acepromazine's duration of action and warrant dose reduction. Young guinea pigs have immature metabolic pathways and should generally not receive acepromazine until they reach appropriate maturity. The veterinarian considers each individual patient's size, age, breed characteristics, and health status when developing the sedation protocol.

Within the sedative and tranquilizer category, several alternative agents offer options when acepromazine is not suitable or when different characteristics are desired for guinea pig patients. Alpha-2 adrenergic agonists including dexmedetomidine (Dexdomitor) and medetomidine provide reliable sedation with the significant advantage of being reversible through specific antagonist administration, allowing rapid recovery when needed. These agents also provide analgesia, which acepromazine lacks. However, alpha-2 agonists cause different cardiovascular effects including initial hypertension and bradycardia, which may make them less suitable for certain patients. Midazolam, a benzodiazepine, provides anxiolysis and muscle relaxation with minimal cardiovascular effects and can be reversed with flumazenil; it is often combined with other agents rather than used alone as its sedative effects in guinea pigs are unreliable as a sole agent.

Opioid medications may be used as part of sedation protocols when analgesia is needed in addition to calming effects. Butorphanol provides mild sedation along with pain control and is frequently combined with acepromazine or other sedatives for pre-anesthetic protocols. Buprenorphine offers longer-lasting analgesia but less sedation. Opioids alone typically do not provide adequate sedation for procedures in guinea pigs and are most effective when combined with other sedative agents. The multimodal approach of combining drugs from different classes allows lower doses of each individual agent, potentially reducing side effects while achieving adequate sedation and analgesia.

General anesthesia using inhalant agents such as isoflurane and sevoflurane provides an alternative when chemical restraint is insufficient or when more invasive procedures are required. Injectable anesthetic protocols may combine agents such as ketamine with sedatives for short procedures not requiring intubation. The choice between sedation-only protocols and full general anesthesia depends on the procedure requirements, duration, and level of patient immobility needed. Supportive care components including warming support, fluid administration, and nutritional support with products like Critical Care are important regardless of which sedation or anesthesia approach is selected. Vitamin C supplementation should continue throughout any treatment period. The exotic veterinarian develops individualized protocols for each patient based on the procedure needs and patient health status.